Bionano genomics announces publication of landmark research study in myelodysplastic syndrome showing ogm data would result in revised prognostic risk classification or additional actionable variants in 28% of study participants

San diego, aug. 01, 2022 (globe newswire) -- bionano genomics, inc. (nasdaq: bngo) today announced the publication of the first study to evaluate the utility of optical genome mapping (ogm) for myelodysplastic syndrome (mds) prognostication. in the peer-reviewed study, published in leukemia, researchers from the university of texas md anderson cancer center reported that when ogm was used instead of karyotyping, 17 to 21% of study subjects had different prognostic risk scores and in 13% of study subjects additional pathogenic variants were revealed. the ogm results were also compared to results of a next-generation sequencing (ngs) panel used for molecular pathology. the comparison to ngs showed that the utility of ogm above and beyond that of karyotyping is not provided by ngs.
BNGO Ratings Summary
BNGO Quant Ranking